Abstract
Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in the pediatric population and recapitulates many of the phenotypic and biological features of embryonic skeletal muscle. RMS is pathologically characterized by myogenic differentiation arrest. Dysregulation of pathways essential for myogenesis like contribute to the tumorigenesis of RMS. The Wnt signaling pathway is one of the major pathways required for normal myogenesis. Aberrant Wnt signaling has also been demonstrated in many types of cancer. The role of Wnt pathway in the pathogenesis of RMS is beginning to be appreciated. This review will go over current knowledge on biological roles of Wnt pathway in RMS and potential translational application in therapeutics.
Keywords: Wnt, rhabdomyosarcoma, cancer, myogenesis.
Current Drug Targets
Title:Wnt Signaling in Rhabdomyosarcoma – A Potential Targeted Therapy Option
Volume: 17 Issue: 11
Author(s): Eleanor Chen
Affiliation:
Keywords: Wnt, rhabdomyosarcoma, cancer, myogenesis.
Abstract: Rhabdomyosarcoma (RMS) is the most common soft tissue malignancy in the pediatric population and recapitulates many of the phenotypic and biological features of embryonic skeletal muscle. RMS is pathologically characterized by myogenic differentiation arrest. Dysregulation of pathways essential for myogenesis like contribute to the tumorigenesis of RMS. The Wnt signaling pathway is one of the major pathways required for normal myogenesis. Aberrant Wnt signaling has also been demonstrated in many types of cancer. The role of Wnt pathway in the pathogenesis of RMS is beginning to be appreciated. This review will go over current knowledge on biological roles of Wnt pathway in RMS and potential translational application in therapeutics.
Export Options
About this article
Cite this article as:
Chen Eleanor, Wnt Signaling in Rhabdomyosarcoma – A Potential Targeted Therapy Option, Current Drug Targets 2016; 17 (11) . https://dx.doi.org/10.2174/1389450116666150630110625
DOI https://dx.doi.org/10.2174/1389450116666150630110625 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
IP6 & Inositol in Cancer Prevention and Therapy
Current Cancer Therapy Reviews From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Modular Nanotransporters for Targeted Intracellular Delivery of Drugs: Folate Receptors as Potential Targets
Current Pharmaceutical Design Structural Heterogeneity and Multifunctionality of Lactoferrin
Current Protein & Peptide Science Drug Delivery Systems and Combination Therapy by Using Vinca Alkaloids
Current Topics in Medicinal Chemistry Insights into a Critical Role of the FOXO3a-FOXM1 Axis in DNA Damage Response and Genotoxic Drug Resistance
Current Drug Targets Targeting the Voltage-Dependent K+ Channels Kv1.3 and Kv1.5 as Tumor Biomarkers for Cancer Detection and Prevention
Current Medicinal Chemistry The Mechanism of Calcitriol in Cancer Prevention and Treatment
Current Medicinal Chemistry Human Apurinic/Apyrimidinic Endonuclease (APE1): An Emerging Anti-Cancer Biomarker
Recent Patents on Biomarkers Rational Design of CPP-based Drug Delivery Systems: Considerations from Pharmacokinetics
Current Pharmaceutical Biotechnology Biosynthetic and Metabolic Alterations in Cancer Growth
Current Angiogenesis (Discontinued) Mechanism of Cancer Drug Resistance and the Involvement of Noncoding RNAs
Current Medicinal Chemistry Is Fibroblast Growth Factor Receptor 4 a Suitable Target of Cancer Therapy?
Current Pharmaceutical Design Inhibitors of Cancer Stem Cells
Anti-Cancer Agents in Medicinal Chemistry Antibiotic Properties and Applications of Lactoferrin
Current Pharmaceutical Design ROCK Inhibitors as Emerging Therapeutic Candidates for Sarcomas
Current Cancer Drug Targets Advances in Anticancer Antibody-Drug Conjugates and Immunotoxins
Recent Patents on Anti-Cancer Drug Discovery PP2A in the Regulation of Cell Motility and Invasion
Current Protein & Peptide Science One Hundred Faces of Cyclopamine
Current Pharmaceutical Design The Role of Cellular Plasticity in Cancer Development
Current Medicinal Chemistry